West Syndrome Global Market Report 2025

West syndrome, also known as infantile spasms, is a rare neurological disorder that typically affects infants within their first year of life. It is characterized by sudden muscle contractions occurring in clusters, abnormal brain wave patterns known as hypsarrhythmia, and developmental regression or stagnation. If left untreated, West syndrome can lead to long-term cognitive and motor impairments.

The primary treatments for West syndrome include anticonvulsants, benzodiazepines, corticosteroids, and vitamin B. Anticonvulsants are a class of drugs designed to prevent or reduce the severity and frequency of seizures in individuals with epilepsy or other seizure disorders, including infantile spasms. The available routes of administration include the parenteral route, oral route, and others. West syndrome treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, home care, and clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The west syndrome market research report is one of a series of new reports from The Business Research Company that provides west syndrome market statistics, including west syndrome industry global market size, regional shares, competitors with a west syndrome market share, detailed west syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the west syndrome industry. This west syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The west syndrome market size has grown strongly in recent years. It will grow from $1.02 billion in 2024 to $1.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing awareness of rare diseases, introduction of acth therapy, development of vigabatrin, rise in genetic studies, establishment of pediatric neurology centers, growth of orphan drug programs, early adoption of ketogenic diet, support from advocacy groups.

The west syndrome market size is expected to see strong growth in the next few years. It will grow to $1.5 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of precision medicine, increasing availability of wearable seizure devices, expansion of rare disease funding, integration of big data analytics, innovation in drug delivery systems, global health initiatives for rare conditions, increasing focus on pediatric healthcare infrastructure. Major trends in the forecast period include AI-assisted eeg analysis, portable and wearable seizure monitoring devices, machine learning for predictive diagnosis, next-generation sequencing for genetic testing, cloud-based data sharing platforms, non-invasive brain stimulation technologies, real-time remote monitoring tools, digital health apps for symptom tracking, 3d bioprinting for brain model research, blockchain for secure patient data management.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. pediatric neurology by driving up the cost of adrenocorticotropic hormone (ACTH) therapies and EEG monitoring systems sourced from Italy and Belgium, exacerbating treatment delays for infantile spasms and increasing specialized care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing investment in research and development for neurological disorders is expected to drive the growth of the West syndrome market in the coming years. Research and development funding for neurological illnesses supports advancements in understanding, diagnosing, and treating neurological conditions. The rise in research and development spending is attributed to the growing prevalence of neurological disorders, technological advancements in medical science, increasing awareness, demand for innovative treatments, and substantial financial support from both government and private sectors. Increased funding drives progress in diagnostics, therapies, and treatment options, contributing to the expansion of the West syndrome market. For example, in May 2023, the National Institute of Neurological Disorders and Stroke (NINDS), a US-based government agency under the National Institutes of Health, received $2.809 billion in funding, with a slight increase to $2.825 billion requested for 2024 to support a wide range of neurological research initiatives. Consequently, the growing research and development investment in neurological illnesses is fostering the growth of the West syndrome market.

Leading companies in the west syndrome market are prioritizing the development of innovative treatments, such as ready-to-use oral solutions of vigabatrin, to enhance ease of administration, ensure accurate dosing, and improve treatment adherence in infants and young children. These formulations are designed to facilitate the delivery of antiepileptic medications, including vigabatrin and adrenocorticotropic hormone (ACTH), in a patient-friendly manner. For instance, in June 2024, Pyros Pharmaceuticals, a US-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for a ready-to-use oral solution of vigabatrin to treat infantile spasms. Vigabatrin works by irreversibly inhibiting GABA transaminase (GABA-T), the enzyme responsible for breaking down gamma-aminobutyric acid (GABA) in the brain. The resulting increase in GABA levels helps suppress the excessive excitatory processes that can trigger seizures.

In December 2024, H. Lundbeck A/S, a Denmark-based pharmaceutical company, acquired Longboard Pharmaceuticals Inc. for $2.6 billion. Through this acquisition, Lundbeck gained access to bexicaserin, a 5-HT2C agonist in development for treating seizures associated with developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies. Longboard Pharmaceuticals Inc. is a US-based clinical-stage biopharmaceutical company specializing in therapies for seizures related to developmental and epileptic encephalopathies (DEEs), including West syndrome.

Major players in the west syndrome market are Takeda Pharmaceuticals, Jazz Pharmaceuticals, UCB S.A., H. Lundbeck A/S, Mallinckrodt Pharmaceuticals plc, Harmony Biosciences Holdings Inc., Nutricia (Ketogenic diet) Ltd., Upsher-Smith Laboratories LLC, Catalyst Pharmaceuticals Inc., SK Biopharmaceuticals Co. Ltd., Cedars Sinai Health System, Marinus Pharmaceuticals Inc., Biocodex S.A., BioPharm Solutions Inc., Cerecin Inc., GW Pharmaceuticals Limited, Anavex Life Sciences Corp, Bio-Pharm Solutions, Ovid Therapeutics Inc., Epygenix Therapeutics Inc., Amzell.

North America was the largest region in the west syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in west syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the west syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The west syndrome market consists of revenues earned by entities by providing services such as neuroimaging technologies, genetic testing services, rehabilitative services, specialized dietary programs, supportive care and patient counseling for managing infantile spasms and associated developmental delays. The market value includes the value of related goods sold by the service provider or included within the service offering. The west syndrome market includes sales of hormone therapies, ketogenic diet and developmental therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

West Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on west syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for west syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The west syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Anticonvulsant; Benzodiazepine; Corticosteroids; Vitamin B
• 2) By Route Of Administration: Parenteral Route; Oral Route; Other Routes Of Administration
• 3) By Distribution Channel: Hospitals Pharmacies; Online Pharmacies; Retail Pharmacies
• 4) By End-User: Hospitals; Homecare; Clinics
• Subsegments:
• 1) By Anticonvulsant: Traditional Anticonvulsants; Newer Anticonvulsants
• 2) By Benzodiazepine: Diazepam; Lorazepam; Clonazepam
• 3) By Corticosteroids: Prednisolone; Adrenocorticotropic Hormone (ACTH); Dexamethasone
• 4) By Vitamin B: Vitamin B6 (Pyridoxine); Vitamin B12 (Cobalamin)
• Companies Mentioned: Takeda Pharmaceuticals; Jazz Pharmaceuticals; UCB S.A.; H. Lundbeck A/S; Mallinckrodt Pharmaceuticals plc; Harmony Biosciences Holdings Inc.; Nutricia (Ketogenic diet) Ltd.; Upsher-Smith Laboratories LLC; Catalyst Pharmaceuticals Inc.; SK Biopharmaceuticals Co. Ltd.; Cedars Sinai Health System; Marinus Pharmaceuticals Inc.; Biocodex S.A.; BioPharm Solutions Inc.; Cerecin Inc.; GW Pharmaceuticals Limited; Anavex Life Sciences Corp; Bio-Pharm Solutions; Ovid Therapeutics Inc.; Epygenix Therapeutics Inc.; Amzell
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.